

# LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE", B/H, SATYAM COMPLEX, SCIENCE CITY ROAD, SOLA, AHMEDABAD-380 060.  
Tel. No. :- 079-67778000, Fax. No.-079-67778062, email id: info@lincolnpharma.com, CIN-L24230GJ1995PLC024288

## UN-AUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED ON 30.06.2015

(Rs. in Lacs)

PARTICULARS	CONSOLIDATED						STANDARD ONE		
	30.06.2015 (Un-Audited)	31.03.2015 (Audited)	30.06.2014 (Un-Audited)	31.03.2015 (Audited)	30.06.2015 (Un-Audited)	31.03.2015 (Audited)	30.06.2014 (Un-Audited)	31.03.2015 (Audited)	
<b>1</b> Income from operations									
(a) Net Sales/Income from operation (Net of excise duty)	7323.41	7869.83	4694.95	26607.45	5844.39	6228.94	4637.06	22325.99	
(b) Other operating income	245.03	-13.23	216.02	718.56	222.90	-111.06	196.90	533.80	
<b>Total Income from operations (net)</b>	<b>7568.44</b>	<b>7856.60</b>	<b>4910.97</b>	<b>27326.01</b>	<b>6067.29</b>	<b>6117.88</b>	<b>4833.96</b>	<b>22859.79</b>	
<b>2</b> Expenses									
(a) Cost of materials consumed	1454.58	1244.20	1226.96	5377.70	1125.60	953.88	969.48	4349.74	
(b) Purchases of stock-in-trade	3508.41	4088.51	1272.97	12307.98	2600.84	2804.04	1702.20	9814.62	
(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-359.37	295.24	277.69	270.55	-272.77	263.26	218.68	193.48	
(d) Employee benefits expense	566.94	442.99	432.46	1787.09	517.92	394.34	379.55	1585.43	
(e) Depreciation and amortisation expenses	114.04	101.18	111.28	456.81	72.04	89.76	70.79	293.01	
(f) Other expenses	1253.44	1056.95	993.68	4303.57	1106.65	1126.70	847.98	4072.06	
<b>Total expenses</b>	<b>6598.04</b>	<b>7228.77</b>	<b>4305.04</b>	<b>24503.70</b>	<b>5150.29</b>	<b>5601.98</b>	<b>4188.68</b>	<b>20308.35</b>	
<b>3</b> Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	<b>1030.40</b>	<b>627.83</b>	<b>605.93</b>	<b>2822.31</b>	<b>917.00</b>	<b>515.90</b>	<b>645.28</b>	<b>2551.44</b>	
<b>4</b> Other Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
<b>5</b> Profit / (Loss) from ordinary activities before finance costs and exceptional items(4 + 3)	<b>1030.40</b>	<b>627.83</b>	<b>605.93</b>	<b>2822.31</b>	<b>917.00</b>	<b>515.90</b>	<b>645.28</b>	<b>2551.44</b>	
<b>6</b> Finance costs	198.90	289.33	184.70	837.74	150.74	227.50	138.10	634.74	
<b>7</b> Profit / (Loss) from ordinary activities after finance costs but before exceptional items(5 - 6)	<b>831.50</b>	<b>338.50</b>	<b>421.23</b>	<b>1984.57</b>	<b>766.26</b>	<b>288.40</b>	<b>507.18</b>	<b>1916.70</b>	
<b>8</b> Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
<b>9</b> Profit / (Loss) from ordinary activities before tax (7 + 8)	<b>831.50</b>	<b>338.50</b>	<b>421.23</b>	<b>1984.57</b>	<b>766.26</b>	<b>288.40</b>	<b>507.18</b>	<b>1916.70</b>	
<b>10</b> Tax expense	176.96	115.44	117.44	480.43	157.96	97.11	122.57	439.40	
<b>11</b> Net Profit / (Loss) from ordinary activities after tax (9 - 10)	<b>654.54</b>	<b>223.06</b>	<b>303.79</b>	<b>1504.14</b>	<b>608.30</b>	<b>191.29</b>	<b>384.61</b>	<b>1477.30</b>	
<b>12</b> Extraordinary items (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
<b>13</b> Net Profit / (Loss) for the period (11 - 12)	<b>654.54</b>	<b>223.06</b>	<b>303.79</b>	<b>1504.14</b>	<b>608.30</b>	<b>191.29</b>	<b>384.61</b>	<b>1477.30</b>	
<b>14</b> Share of profit / (loss) of associates*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
<b>15</b> Minority interest	0.66	2.94	-19.05	2.93	0.00	0.00	0.00	0.00	
<b>16</b> Net Profit / (Loss) after taxes, minority interest and shares of profit/(loss) of associates ((13 + 14 + 15)*)	<b>653.88</b>	<b>220.12</b>	<b>322.84</b>	<b>1501.21</b>	<b>608.30</b>	<b>191.29</b>	<b>384.61</b>	<b>1477.30</b>	
<b>17</b> Paid-up equity share capital of face value Rs. 10/- each	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	
<b>18</b> Reserve excluding Revaluation Reserves as per balance sheet of Previous a/c. Year	4.01	1.35	1.98	9.20	3.73	1.17	2.36	9.06	
<b>19</b> i) a) Basic and diluted EPS before Extraordinary Items (10/- each) and Prior period Adjustment (Not Annualised)	4.01	1.35	1.98	9.20	3.73	1.17	2.36	9.06	
ii) b) Basic and diluted EPS after Extraordinary Items (10/- each) and Prior period Adjustment (Not Annualised)	4.01	1.35	1.98	9.20	3.73	1.17	2.36	9.06	
<b>PART - II</b>									
<b>A</b> <b>PARTICULARS OF SHAREHOLDING</b>									
<b>1</b> Public Shareholding:									
-Number of Shares	10350573	10350573	10984449	10350573	10350573	10350573	10984449	10350573	
-Percentage of Shareholding	63.46	63.46	67.34	63.46	63.46	63.46	67.34	63.46	
<b>2</b> Promoters and Promoter group Shareholding:									
a) Pledged/Encumbered									
-Number of shares	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	
-Percentage of Shareholding (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	
b) Non-encumbered									
-Number of Shares	5960227	5960227	5326351	5960227	5960227	5960227	5326351	5960227	
-Percentage of Shareholding (as a % of the total shareholding of promoter and promoter group)	36.54	36.54	32.66	36.54	36.54	36.54	32.66	36.54	
<b>Particulars</b>									
<b>B</b> <b>INVESTOR COMPLAINTS</b>									
Pending at the beginning of the quarter	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	
Received during the quarter	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	
Disposed of during the quarter	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	
Remaining unresolved at the end of the quarter	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	

**NOTES:-**

- The above results were reviewed by the audit committee and approved by the Board of Directors at its meeting held on 04.08.2015.
- Previous year figures are regrouped/reclassified to confirm to the current year's presentation.
- Since the revenue from different segment is less than 10% of total revenue, segment wise results are not given.
- Statutory Auditors has carried out limited review for the quarterly result for quarter ended 30.06.2015.
- Consolidated results includes results of its two subsidiary Company.
- Company has opted to publish consolidated Results for the year 2015-16.

for LINCOLN PHARMACEUTICALS LIMITED  
(Mahendra G. Patel)  
Managing Director

